Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") today reported favorable safety and tolerability results from the singleascending dose (SAD) cohorts of the Phase 1 study in healthy volunteers with CDI-988, its potent, oral, panviral protease inhibitor. CDI-988 was specifically designed and developed using Cocrystal's proprietary structure-based drug discovery platform technology as a broad-spectrum antiviral inhibitor to a highly conserve ...